Trial Review

Technical difficulties have been reported by some users of the search function and is being investigated by technical staff. Thank you for your patience and apologies for any inconvenience caused.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT05100862




Registration number
NCT05100862
Ethics application status
Date submitted
27/09/2021
Date registered
29/10/2021
Date last updated
6/06/2024

Titles & IDs
Public title
A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma
Scientific title
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma
Secondary ID [1] 0 0
CTR20232545
Secondary ID [2] 0 0
BGB-3111-308
Universal Trial Number (UTN)
Trial acronym
MAHOGANY
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Relapsed/Refractory Follicular Lymphoma 0 0
Marginal Zone Lymphoma 0 0
Condition category
Condition code
Cancer 0 0 0 0
Lymphoma (non Hodgkin's lymphoma) - High grade lymphoma
Cancer 0 0 0 0
Lymphoma (non Hodgkin's lymphoma) - Low grade lymphoma

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Zanubrutinib
Treatment: Drugs - Rituximab
Treatment: Drugs - Lenalidomide
Treatment: Drugs - Obinutuzumab

Experimental: Follicular Lymphoma Arm A: Zanubrutinib plus Obinutuzumab - Participants will receive zanubrutinib and Obinutuzumab. Following the completion of the combination treatment, participants will continue receiving zanubrutinib monotherapy until confirmed disease progression, unacceptable toxicity, withdrawal of consent, or study termination, whichever occurs first.

Active Comparator: Follicular Lymphoma Arm B: Lenalidomide plus Rituximab - Participants will receive lenalidomide and rituximab.

Experimental: Marginal Zone Lymphoma Arm C: Zanubrutinib plus Rituximab - Participants will receive zanubrutinib and rituximab. Following the completion of the combination treatment, participants will continue receiving zanubrutinib monotherapy until confirmed disease progression, unacceptable toxicity, withdrawal of consent, or study termination, whichever occurs first.

Active Comparator: Marginal Zone Lymphoma Arm D: Lenalidomide plus Rituximab - Participants will receive lenalidomide and rituximab.


Treatment: Drugs: Zanubrutinib
Zanubrutinib will be administered orally as two 80-milligram (mg) capsules twice a day (160 mg twice a day) or four 80-mg capsules once a day (320 mg once a day) continuously in repeated 28-day cycles.

Treatment: Drugs: Rituximab
Rituximab will be administered intravenously at a dose of 375 mg/meter squared on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. Each cycle is 28 days in length.

Treatment: Drugs: Lenalidomide
Lenalidomide will be administered orally as 20-mg capsules (10 mg if creatinine clearance = 30 mL/min but < 60 mL/min) once a day on Days 1 to 21 of each 28-day cycle for a total of 12 cycles.

Treatment: Drugs: Obinutuzumab
Obinutuzumab will be administered at a dose of 1000 mg on Cycle 1 Days 1, 8, 15 and then on Cycles 2 to 6 Day 1.
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Progression-free Survival As Determined By A Blinded Independent Review Committee (BIRC)
Timepoint [1] 0 0
Approximately 78 months
Secondary outcome [1] 0 0
Progression-free Survival As Determined By Investigator Assessment
Timepoint [1] 0 0
Approximately 87 months
Secondary outcome [2] 0 0
Duration Of Response As Determined By BIRC And By Investigator Assessment
Timepoint [2] 0 0
Approximately 87 months
Secondary outcome [3] 0 0
Overall Response Rate As Determined By BIRC And By Investigator Assessment
Timepoint [3] 0 0
Approximately 87 months
Secondary outcome [4] 0 0
Complete Response Rate As Determined By BIRC And By Investigator Assessment
Timepoint [4] 0 0
Approximately 87 months
Secondary outcome [5] 0 0
Time To Response As Determined By BIRC And By Investigator Assessment
Timepoint [5] 0 0
Approximately 87 months
Secondary outcome [6] 0 0
Time to Next Ant-Lymphoma Treatment
Timepoint [6] 0 0
Approximately 87 months
Secondary outcome [7] 0 0
Overall Survival
Timepoint [7] 0 0
Approximately 87 months
Secondary outcome [8] 0 0
Health-related Quality Of Life (HRQoL) Using EORTC QLQ-C30)
Timepoint [8] 0 0
Approximately 87 months
Secondary outcome [9] 0 0
HRQoL Using European Quality of Life 5 Dimension 5 Level Questionnaire [EQ 5D 5L)
Timepoint [9] 0 0
Approximately 87 months
Secondary outcome [10] 0 0
HRQoL Using National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy Lymphoma Symptom Index-18 [FLymSI 18)
Timepoint [10] 0 0
Approximately 87 months
Secondary outcome [11] 0 0
Number of Participants Experiencing Adverse Events (AEs)
Timepoint [11] 0 0
From first dose to 28 days after the last dose of zanubrutinib or lenalidomide, 90 days after the last dose of obinutuzumab or rituximab, or until the date of confirmed disease progression, whichever comes later (Approximately 87 months)

Eligibility
Key inclusion criteria
Key

- Histologically confirmed grade 1-3a FL or MZL

- Previously treated with = 1 line of systemic therapy including anti-CD20 agent. Must
have a documented failure to achieve at least partial response during the most recent
systemic therapy or documented progressive disease after the most recent systemic
therapy

- Need for systemic therapy for FL or MZL

- Measurable disease by computed tomography or magnetic resonance imaging

- Adequate bone marrow, liver and renal function

Key
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Transformation to aggressive lymphoma

- Requiring ongoing need for corticosteroid treatment

- Clinically significant cardiovascular disease

- Prior malignancy within the past 2 years

- Active fungal, bacterial, and/or viral infection that requires systemic therapy

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
10/03/2022
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
1/06/2030
Actual
Sample size
Target
750
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,QLD,VIC,WA
Recruitment hospital [1] 0 0
Concord Repatriation General Hospital - Concord
Recruitment hospital [2] 0 0
Gosford Hospital - Gosford
Recruitment hospital [3] 0 0
St George Hospital - Kogarah
Recruitment hospital [4] 0 0
Orange Health Hospital - Orange
Recruitment hospital [5] 0 0
Port Macquarie Base Hospital - Port Macquarie
Recruitment hospital [6] 0 0
Westmead Hospital - Westmead
Recruitment hospital [7] 0 0
Sunshine Coast Hospital and Health Service - Birtinya
Recruitment hospital [8] 0 0
Townsville University Hospital - Douglas
Recruitment hospital [9] 0 0
Monash Health - Clayton
Recruitment hospital [10] 0 0
St Vincents Hospital Melbourne - Fitzroy
Recruitment hospital [11] 0 0
Austin Health - Heidelberg
Recruitment hospital [12] 0 0
Cabrini Hospital Malvern - Malvern
Recruitment hospital [13] 0 0
Epworth Freemasons - Melbourne
Recruitment hospital [14] 0 0
The Alfred Hospital - Melbourne
Recruitment hospital [15] 0 0
Royal Perth Hospital - Perth
Recruitment hospital [16] 0 0
Perth Blood Institute - West Perth
Recruitment hospital [17] 0 0
La Trobe Regional Hospital - Melbourne
Recruitment postcode(s) [1] 0 0
2139 - Concord
Recruitment postcode(s) [2] 0 0
2250 - Gosford
Recruitment postcode(s) [3] 0 0
2217 - Kogarah
Recruitment postcode(s) [4] 0 0
2800 - Orange
Recruitment postcode(s) [5] 0 0
2444 - Port Macquarie
Recruitment postcode(s) [6] 0 0
2145 - Westmead
Recruitment postcode(s) [7] 0 0
4575 - Birtinya
Recruitment postcode(s) [8] 0 0
4814 - Douglas
Recruitment postcode(s) [9] 0 0
3168 - Clayton
Recruitment postcode(s) [10] 0 0
3065 - Fitzroy
Recruitment postcode(s) [11] 0 0
3084 - Heidelberg
Recruitment postcode(s) [12] 0 0
3144 - Malvern
Recruitment postcode(s) [13] 0 0
3002 - Melbourne
Recruitment postcode(s) [14] 0 0
3004 - Melbourne
Recruitment postcode(s) [15] 0 0
6000 - Perth
Recruitment postcode(s) [16] 0 0
6005 - West Perth
Recruitment postcode(s) [17] 0 0
3844 - Melbourne
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
California
Country [2] 0 0
United States of America
State/province [2] 0 0
Florida
Country [3] 0 0
United States of America
State/province [3] 0 0
Georgia
Country [4] 0 0
United States of America
State/province [4] 0 0
Indiana
Country [5] 0 0
United States of America
State/province [5] 0 0
Iowa
Country [6] 0 0
United States of America
State/province [6] 0 0
Kansas
Country [7] 0 0
United States of America
State/province [7] 0 0
Maryland
Country [8] 0 0
United States of America
State/province [8] 0 0
Michigan
Country [9] 0 0
United States of America
State/province [9] 0 0
Mississippi
Country [10] 0 0
United States of America
State/province [10] 0 0
Missouri
Country [11] 0 0
United States of America
State/province [11] 0 0
Montana
Country [12] 0 0
United States of America
State/province [12] 0 0
Nebraska
Country [13] 0 0
United States of America
State/province [13] 0 0
Nevada
Country [14] 0 0
United States of America
State/province [14] 0 0
New Jersey
Country [15] 0 0
United States of America
State/province [15] 0 0
New York
Country [16] 0 0
United States of America
State/province [16] 0 0
Ohio
Country [17] 0 0
United States of America
State/province [17] 0 0
Pennsylvania
Country [18] 0 0
United States of America
State/province [18] 0 0
South Dakota
Country [19] 0 0
United States of America
State/province [19] 0 0
Texas
Country [20] 0 0
United States of America
State/province [20] 0 0
Washington
Country [21] 0 0
Argentina
State/province [21] 0 0
Buenos Aires
Country [22] 0 0
Argentina
State/province [22] 0 0
Caba
Country [23] 0 0
Austria
State/province [23] 0 0
St Poelten
Country [24] 0 0
Austria
State/province [24] 0 0
Wien
Country [25] 0 0
Belgium
State/province [25] 0 0
Anderlecht
Country [26] 0 0
Belgium
State/province [26] 0 0
Brugge
Country [27] 0 0
Belgium
State/province [27] 0 0
Gent
Country [28] 0 0
Brazil
State/province [28] 0 0
Barretos
Country [29] 0 0
Brazil
State/province [29] 0 0
Blumenau
Country [30] 0 0
Brazil
State/province [30] 0 0
Botucatu
Country [31] 0 0
Brazil
State/province [31] 0 0
Brasilia
Country [32] 0 0
Brazil
State/province [32] 0 0
Campinas
Country [33] 0 0
Brazil
State/province [33] 0 0
Caxias do Sul
Country [34] 0 0
Brazil
State/province [34] 0 0
Curitiba
Country [35] 0 0
Brazil
State/province [35] 0 0
Florianopolis
Country [36] 0 0
Brazil
State/province [36] 0 0
Porto Alegre
Country [37] 0 0
Brazil
State/province [37] 0 0
Porto Velho
Country [38] 0 0
Brazil
State/province [38] 0 0
Recife
Country [39] 0 0
Brazil
State/province [39] 0 0
Ribeirao Preto
Country [40] 0 0
Brazil
State/province [40] 0 0
Rio de Janeiro
Country [41] 0 0
Brazil
State/province [41] 0 0
Salvador
Country [42] 0 0
Brazil
State/province [42] 0 0
Sao Paulo
Country [43] 0 0
Brazil
State/province [43] 0 0
Vitoria
Country [44] 0 0
China
State/province [44] 0 0
Anhui
Country [45] 0 0
China
State/province [45] 0 0
Beijing
Country [46] 0 0
China
State/province [46] 0 0
Chongqing
Country [47] 0 0
China
State/province [47] 0 0
Guangdong
Country [48] 0 0
China
State/province [48] 0 0
Heilongjiang
Country [49] 0 0
China
State/province [49] 0 0
Henan
Country [50] 0 0
China
State/province [50] 0 0
Hubei
Country [51] 0 0
China
State/province [51] 0 0
Hunan
Country [52] 0 0
China
State/province [52] 0 0
Jiangsu
Country [53] 0 0
China
State/province [53] 0 0
Jiangxi
Country [54] 0 0
China
State/province [54] 0 0
Jilin
Country [55] 0 0
China
State/province [55] 0 0
Liaoning
Country [56] 0 0
China
State/province [56] 0 0
Shandong
Country [57] 0 0
China
State/province [57] 0 0
Shanghai
Country [58] 0 0
China
State/province [58] 0 0
Shanxi
Country [59] 0 0
China
State/province [59] 0 0
Sichuan
Country [60] 0 0
China
State/province [60] 0 0
Zhejiang
Country [61] 0 0
Czechia
State/province [61] 0 0
Hradec Kralove
Country [62] 0 0
Czechia
State/province [62] 0 0
Olomouc
Country [63] 0 0
France
State/province [63] 0 0
Antony
Country [64] 0 0
France
State/province [64] 0 0
Le Mans
Country [65] 0 0
France
State/province [65] 0 0
Montpellier Cedex
Country [66] 0 0
France
State/province [66] 0 0
Nice
Country [67] 0 0
France
State/province [67] 0 0
Paris
Country [68] 0 0
France
State/province [68] 0 0
Strasbourg
Country [69] 0 0
France
State/province [69] 0 0
VandoeuvrelesNancy
Country [70] 0 0
Georgia
State/province [70] 0 0
Batumi
Country [71] 0 0
Georgia
State/province [71] 0 0
Kutaisi
Country [72] 0 0
Georgia
State/province [72] 0 0
Tbilisi
Country [73] 0 0
Ireland
State/province [73] 0 0
Dublin
Country [74] 0 0
Ireland
State/province [74] 0 0
Waterford
Country [75] 0 0
Israel
State/province [75] 0 0
Afula
Country [76] 0 0
Israel
State/province [76] 0 0
Ashdod
Country [77] 0 0
Israel
State/province [77] 0 0
Jerusalem
Country [78] 0 0
Israel
State/province [78] 0 0
Petach Tikva
Country [79] 0 0
Israel
State/province [79] 0 0
Ramat gan
Country [80] 0 0
Israel
State/province [80] 0 0
Tel Aviv
Country [81] 0 0
Italy
State/province [81] 0 0
Aviano
Country [82] 0 0
Italy
State/province [82] 0 0
Bologna
Country [83] 0 0
Italy
State/province [83] 0 0
Milano
Country [84] 0 0
Italy
State/province [84] 0 0
Novara
Country [85] 0 0
Italy
State/province [85] 0 0
Padova
Country [86] 0 0
Italy
State/province [86] 0 0
Pavia
Country [87] 0 0
Italy
State/province [87] 0 0
Reggio Emilia
Country [88] 0 0
Italy
State/province [88] 0 0
Udine
Country [89] 0 0
Italy
State/province [89] 0 0
Varese
Country [90] 0 0
Korea, Republic of
State/province [90] 0 0
Busan Gwang'yeogsi
Country [91] 0 0
Korea, Republic of
State/province [91] 0 0
Gyeonggido
Country [92] 0 0
Korea, Republic of
State/province [92] 0 0
Gyeongsangbukdo
Country [93] 0 0
Korea, Republic of
State/province [93] 0 0
Gyeongsangnamdo
Country [94] 0 0
Korea, Republic of
State/province [94] 0 0
Jeonranamdo
Country [95] 0 0
Korea, Republic of
State/province [95] 0 0
Seoul Teugbyeolsi
Country [96] 0 0
Poland
State/province [96] 0 0
Katowice
Country [97] 0 0
Poland
State/province [97] 0 0
Krakow
Country [98] 0 0
Portugal
State/province [98] 0 0
Almada
Country [99] 0 0
Portugal
State/province [99] 0 0
Porto
Country [100] 0 0
Portugal
State/province [100] 0 0
VILA NOVA DE GAIA Porto
Country [101] 0 0
Puerto Rico
State/province [101] 0 0
Rio Piedras
Country [102] 0 0
Puerto Rico
State/province [102] 0 0
San Juan
Country [103] 0 0
Romania
State/province [103] 0 0
Bucharest
Country [104] 0 0
Romania
State/province [104] 0 0
ClujNapoca
Country [105] 0 0
Romania
State/province [105] 0 0
Iasi
Country [106] 0 0
Romania
State/province [106] 0 0
Oradea
Country [107] 0 0
Spain
State/province [107] 0 0
Badalona
Country [108] 0 0
Spain
State/province [108] 0 0
Burgos
Country [109] 0 0
Spain
State/province [109] 0 0
Cadiz
Country [110] 0 0
Spain
State/province [110] 0 0
Granada
Country [111] 0 0
Spain
State/province [111] 0 0
Hospitalet de LLobregat
Country [112] 0 0
Spain
State/province [112] 0 0
Leon
Country [113] 0 0
Spain
State/province [113] 0 0
Madrid
Country [114] 0 0
Spain
State/province [114] 0 0
Murcia
Country [115] 0 0
Spain
State/province [115] 0 0
Pamplona
Country [116] 0 0
Spain
State/province [116] 0 0
Pozuelo de Alarcon
Country [117] 0 0
Spain
State/province [117] 0 0
Salamanca
Country [118] 0 0
Spain
State/province [118] 0 0
Sevilla
Country [119] 0 0
Spain
State/province [119] 0 0
Terassa
Country [120] 0 0
Switzerland
State/province [120] 0 0
Fribourg
Country [121] 0 0
Switzerland
State/province [121] 0 0
La ChauxdeFonds
Country [122] 0 0
United Kingdom
State/province [122] 0 0
Glasgow
Country [123] 0 0
United Kingdom
State/province [123] 0 0
Greater Manchester
Country [124] 0 0
United Kingdom
State/province [124] 0 0
Huddersfield
Country [125] 0 0
United Kingdom
State/province [125] 0 0
Inverness
Country [126] 0 0
United Kingdom
State/province [126] 0 0
Leeds
Country [127] 0 0
United Kingdom
State/province [127] 0 0
London
Country [128] 0 0
United Kingdom
State/province [128] 0 0
Plymouth
Country [129] 0 0
United Kingdom
State/province [129] 0 0
Southampton

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
BeiGene
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of the study is to compare the efficacy of zanubrutinib plus obinutuzumab versus
lenalidomide plus rituximab (R^2) in participants with relapsed/refractory (R/R) follicular
lymphoma (FL), as measured by progression-free survival as determined by an independent
review committee in accordance with the 2014 modification of the International Working Group
on non-Hodgkin lymphoma (NHL) Criteria based on n positron emission tomography and computed
tomography (PET/CT), and to compare the efficacy of zanubrutinib plus rituximab versus R^2 in
participants with R/R marginal zone lymphoma (MZL), as measured by progression free survival
(PFS) assessed by IRC in accordance with CT-based Lugano 2014 Criteria.
Trial website
https://clinicaltrials.gov/ct2/show/NCT05100862
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Study Director
Address 0 0
BeiGene
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Study Director BeiGene
Address 0 0
Country 0 0
Phone 0 0
1-877-828-5568
Fax 0 0
Email 0 0
clinicaltrials@beigene.com
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT05100862